Selective glucocorticoid receptor agonists for the treatment of inflammatory bowel disease: Studies in mice with acute trinitrobenzene sulfonic acid colitis

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 1, 2012, Pages 68-80

  Reuter, Kerstin C ^a   Grunwitz, Christian R ^a   Kaminski, Bettina M ^a   Steinhilber, Dieter ^a   Radeke, Heinfried H ^a,b   Stein, Jur̈gen ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b Crohn Colitis Centrum Frankfurt   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(4 ACETOPHENYL) 2 CHLORO N METHYL]ETHYLAMMONIUM CHLORIDE; 4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; ANTIINFLAMMATORY AGENT; CASPASE 8; CORTICOTROPIN; CYCLOOXYGENASE 2; DEXAMETHASONE; GAMMA INTERFERON; GLUCOSE; GLYCOGEN; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR RELA; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLITIS; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CYTOKINE PRODUCTION; DIABETOGENESIS; DISEASE MODEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RESISTANCE; ENTERITIS; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GLUCOCORTICOID RESISTANCE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCOGEN LIVER LEVEL; HUMAN; HUMAN CELL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOW DRUG DOSE; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAT GENE; TH1 CELL; TH2 CELL; TRANSACTIVATION; WASTING SYNDROME;

ACUTE DISEASE; ANIMALS; BENZOFURANS; BENZOXAZINES; CACO-2 CELLS; CELLS, CULTURED; COLITIS; HEK293 CELLS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MICE; MICE, INBRED BALB C; RECEPTORS, GLUCOCORTICOID; TREATMENT OUTCOME; TRINITROBENZENESULFONIC ACID;

EID: 84858684891     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.183947     Document Type: Article

References (41)

1. Barnes PJ (2006) Corticosteroid effects on cell signalling. Eur Respir J 27:413-426.
2. Barnes PJ and Adcock IM (2009) Glucocorticoid resistance in inflammatory diseases. Lancet 373:1905-1917.
3. Bergann T, Zeissig S, Fromm A, Richter JF, Fromm M, and Schulzke JD (2009) Glucocorticoids and tumor necrosis factor-α synergize to induce absorption by the epithelial sodium channel in the colon. Gastroenterology 136:933-942.
4. Bradley PP, Priebat DA, Christensen RD, and Rothstein G (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78:206-209. (Pubitemid 12171880)
5. Daniel C, Radeke HH, Sartory NA, Zahn N, Zuegel U, Steinmeyer A, and Stein J (2006) The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J Pharmacol Exp Ther 319:622-631.
6. De Bosscher K, Vanden BergheW, Beck IM, Van Molle W, Hennuyer N, Hapgood J, Libert C, Staels B, Louw A, and Haegeman G (2005) A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A 102:15827-15832. (Pubitemid 41552827)
7. Dewint P, Gossye V, De Bosscher K, Vanden Berghe W, Van Beneden K, Deforce D, Van Calenbergh S, Müller-Ladner U, Vander Cruyssen B, Verbruggen G, et al. (2008) A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol 180:2608-2615.
8. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG, and Van Rees EP (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114:385-391. (Pubitemid 28539597)
9. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, and Sandborn WJ (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121:255-260. (Pubitemid 32729372)
10. Fuqua JS, Rotenstein D, and Lee PA (2010) Duration of suppression of adrenal steroids after glucocorticoid administration. Int J Pediatr Endocrinol 2010:712549.
11. Goldstein RE, Rossetti L, Palmer BA, Liu R, Massillon D, Scott M, Neal D, Williams P, Peeler B, and Cherrington AD (2002) Effects of fasting and glucocorticoids on hepatic gluconeogenesis assessed using two independent methods in vivo. Am J Physiol Endocrinol Metab 283:E946-E957. (Pubitemid 35216952)
12. Gossye V, Elewaut D, Van Beneden K, Dewint P, Haegeman G, and De Bosscher K (2010) A plant-derived glucocorticoid receptor modulator attenuates inflammation without provoking ligand-induced resistance. Ann Rheum Dis 69:291-296.
13. Heck S, Kullmann M, Gast A, Ponta H, Rahmsdorf HJ, Herrlich P, and Cato AC (1994) A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J 13:4087-4095. (Pubitemid 24275865)
14. Humphrey EL, Williams JH, Davie MW, and Marshall MJ (2006) Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 38:652-661.
15. Jacobson PB, von Geldern TW, Ohman L, Osterland M, Wang J, Zinker B, Wilcox D, Nguyen PT, Mika A, Fung S, et al. (2005) Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. J Pharmacol Exp Ther 314:191-200. (Pubitemid 41058255)
16. Keppler D and Decker K (1994) Glycogen: determination with amyloglucosidase, in Methods of Enzymatic Analysis (Bergmeyer HU, ed) pp 1127-1131, John Wiley & Sons, New York.
17. López FJ, Ardecky RJ, Bebo B, Benbatoul K, De Grandpre L, Liu S, Leibowitz MD, Marschke K, Rosen J, Rungta D, et al. (2008) LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo. Endocrinology 149:2080-2089. (Pubitemid 351574480)
18. Louw A, Allie F, Swart AC, and Swart P (2000a) Inhibition of cytochrome P450c11 by biogenic amines and an aziridine precursor, 2-(4-acetoxyphenyl)-2- chloro-N-methyl-ethylammonium chloride. Endocr Res 26:729-736. (Pubitemid 32053096)
19. Louw A and Swart P (1999) Salsola tuberculatiformis Botschantzev and an aziridine precursor analog mediate the in vivo increase in free corticosterone and decrease in corticosteroid-binding globulin in female Wistar rats. Endocrinology 140:2044-2053. (Pubitemid 30636441)
20. Louw A, Swart P, and Allie F (2000b) Influence of an aziridine precursor on the in vitro binding parameters of rat and ovine corticosteroid-binding globulin (CBG). Biochem Pharmacol 59:167-175.
21. MacDermott RP (1996) Alterations of the mucosal immune system in inflammatory bowel disease. J Gastroenterol 31:907-916.
22. Macfarlane DP, Forbes S, and Walker BR (2008) Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 197:189-204. (Pubitemid 351696232)
23. Martins NB and Peppercorn MA (2004) Inflammatory bowel disease. Am J Manag Care 10:544-552. (Pubitemid 39097144)
24. Miner JN, Hong MH, and Negro-Vilar A (2005) New and improved glucocorticoid receptor ligands. Expert Opin Investig Drugs 14:1527-1545. (Pubitemid 41749197)
25. Neurath MF, Finotto S, and Glimcher LH (2002) The role of Th1/Th2 polarization in mucosal immunity. Nat Med 8:567-573. (Pubitemid 34633433)
26. Owen HC, Miner JN, Ahmed SF, and Farquharson C (2007) The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol 264:164-170. (Pubitemid 46097311)
27. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, et al. (1998a) DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93:531-541. (Pubitemid 28240715)
28. Reichardt HM, Kaestner KH, Wessely O, Gass P, Schmid W, and Schütz G (1998b) Analysis of glucocorticoid signalling by gene targeting. J Steroid Biochem Mol Biol 65:111-115. (Pubitemid 28335596)
29. Robertson S, Allie-Reid F, Vanden Berghe W, Visser K, Binder A, Africander D, Vismer M, De Bosscher K, Hapgood J, Haegeman G, et al. (2010) Abrogation of glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of compound A. J Biol Chem 285:8061-8075.
30. Rogler G (2010) Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol 24:157-165.
31. Schäcke H, Berger M, Rehwinkel H, and Asadullah K (2007) Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 275:109-117. (Pubitemid 47259282)
32. Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, and Asadullah K (2004) Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 101:227-232. (Pubitemid 38084232)
33. Schäcke H, Zollner TM, Döcke WD, Rehwinkel H, Jaroch S, Skuballa W, Neuhaus R, May E, Zügel U, and Asadullah K (2009) Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 158:1088-1103.
34. Schreiber S, Nikolaus S, and Hampe J (1998) Activation of nuclear factor κB inflammatory bowel disease. Gut 42:477-484. (Pubitemid 28186562)
35. Stanbury RM and Graham EM (1998) Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol 82:704-708. (Pubitemid 28306665)
36. Strober W, Fuss I, and Mannon P (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117:514-521. (Pubitemid 46348505)
37. Swart P, Swart AC, Louw A, and van der Merwe KJ (2003) Biological activities of the shrub Salsola tuberculatiformis Botsch.: contraceptive or stress alleviator? Bioessays 25:612-619. (Pubitemid 36702329)
38. van Loo G, Sze M, Bougarne N, Praet J, Mc Guire C, Ullrich A, Haegeman G, Prinz M, Beyaert R, and De Bosscher K (2010) Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis. Mol Endocrinol 24:310-322.
39. Wüst S, Tischner D, John M, Tuckermann JP, Menzfeld C, Hanisch UK, van den Brandt J, Lühder F, and Reichardt HM (2009) Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PLoS One 4:e8202.
40. Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT Jr, and Budunova I (2008) Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells. Cancer Res 68:4763-4773.
41. Zhang Z, Zhang ZY, and Schluesener HJ (2009) Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol 183:3081-3091.